Biotinylated Therapeutic Polymers for Selective Antimicrobial Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antimicrobial polymers face challenges with low selectivity and high hemotoxicity to mammalian cells due to non-degradability, while antimicrobial peptides have limitations in clinical applications due to cytotoxicity and high production costs, and P. aeruginosa infections are difficult to treat due to biofilm formation and resistance to antibiotics.
Innovation Solution
Development of biotinylated polyguanidinium polymers through ring opening polymerization, which enhance uptake by pathogens and cancer cells via natural molecular trafficking mechanisms, and formation of coacervate complexes with anionic polymers to reduce toxicity and improve selectivity and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-degradable polymers such as polyethylenimines and polyacrylates are used for antimicrobial therapy, then antimicrobial activity is improved, but selectivity decreases and hemotoxicity to mammalian cells increases
Solution Approach 1:
The patent changes the chemical composition parameter by using amino acid residues (lysine, arginine, histidine) instead of non-degradable synthetic polymers. This natural polymer composition provides biodegradability and reduced toxicity while maintaining antimicrobial activity through cationic charges and amphiphilic properties.
Solution Approach 2:
The patent employs degradable polymers that break down into amino acid residues after performing their antimicrobial function. This discarding mechanism eliminates long-term toxicity concerns while the breakdown products (amino acids) are biocompatible and can be recovered by mammalian cells.
2Object-affected harmful factors
If antimicrobial peptides with degradable polypeptide backbones are used, then selectivity and biocompatibility are improved, but production cost increases and clinical application is limited
Solution Approach 1:
The patent creates polymers with multiple functional groups (cationic charges, hydrophobic regions, hydrogen bonding capacity) that provide both antimicrobial activity and biocompatibility. This multi-functionality in a single polymer structure achieves the selectivity of peptides without the high production costs and enzymatic degradation issues.
Solution Approach 2:
The patent synthesizes composite polymer structures combining hydrophobic amino acid residues (for membrane interaction) with cationic charged residues (for electrostatic attraction to microbial surfaces). This composite approach at the molecular level achieves both efficacy and selectivity.
3Reliability
If traditional antibiotics are used to treat P. aeruginosa infections, then initial treatment is effective, but bacteria develop strong resistance and form biofilms that shield colonies from antibiotics
Solution Approach 1:
The patent extracts the problematic non-degradable backbone from antimicrobial polymers and replaces it with degradable amino acid-based structures. This removal of the persistent component eliminates the basis for long-term resistance development while maintaining short-term antimicrobial efficacy.
Solution Approach 2:
The patent converts the typically harmful permanent presence of antibiotics (which selects for resistance) into a beneficial temporary action. The degradable polymers perform their antimicrobial function and then disappear, preventing the selective pressure that leads to resistance development.
4Reliability
If polyguanidinium polymers are used to damage microbes via membrane lysis, then antimicrobial efficacy is improved, but selectivity between pathogenic bacteria and mammalian cells decreases
Solution Approach 1:
The patent creates local quality differences by incorporating specific amino acid sequences with distinct properties (cationic, hydrophobic, hydrogen-bonding) at different positions along the polymer chain. This local differentiation enables selective interaction with microbial surfaces while sparing mammalian cells through nuanced molecular recognition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biotinylated polymers demonstrate enhanced therapeutic efficacy against a broad spectrum of pathogens and cancer cells with reduced toxicity to mammalian cells, and coacervate complexes provide stable, neutral delivery systems for improved selectivity and safety.
Implementation Method 1
enhance uptake by pathogens and cancer cells via natural molecular trafficking mechanisms
Implementation Method 2
formation of coacervate complexes with anionic polymers to reduce toxicity and improve selectivity and efficacy
Data Source
AI summary
The subject disclosure is directed to techniques for enhancing the selectivity and efficacy of therapeutic polymers against a broad spectrum of pathogens and cancer cell lines. According to an embodiment, a method is provided that comprises forming a therapeutic polymer based on polymerization of a plurality of therapeutic monomers, wherein the therapeutic polymer provides a therapeutic functionality. The method further comprises attaching biotin to the therapeutic polymer, resulting in a biotin-functionalized therapeutic polymer, wherein the biotin-functionalized therapeutic polymer provides greater therapeutic efficacy relative to the therapeutic polymer.